The STAM model as a model for hepatocellular carcinoma
We would like to introduce today a NASH-HCC model from SMC Laboratories (“STAMTM mice”) for your oncology R&D projects.
The model has the following features compared with other HCC models.
STAM model;
– shows prompt (by 20 wks of age) and definite (nearly 100%) disease development to HCC
– is non-genetic, NASH-associated cancer model that has an advantage of naturally-occurring tumor microenvironment
– allows a flexible treatment design for HCC therapeutics (preventive regimen/therapeutic regimen)
Please find below the comparison table of STAM and other HCC models.
DEN: Diethylnitrosamine, TAA: Thioacetamide
[1] Takakura K., et al., World J. Gastroenterol 24: 1989–1994
[2] Heindryckx F., et al., Int J Exp Path 90:367, 2009
In addition to the above, human HCC markers such as AFP, Glypican-3 and Glutamine synthetase are observed in this model.
This, along with our facility equipped with CT scan facility for small animals, enables multifaceted and accurate assessment of tumor development.
We believe that a pharmacological study using this model could help you progress with the research and development of your compound.
Please don’t hesitate to contact me if you would like further information on any of these models or our services.